Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
private:glycomiratherapeuticsinc.-2 | 1464055 | May 25th, 2019 12:00AM | GlycoMira Therapeutics, Inc. | 66 | 7.00 | Open | Pharmaceuticals | May 25th, 2019 09:08AM | May 25th, 2019 09:08AM | GlycoMira Therapeutics is developing therapeutics for Mucosal Diseases. Current R&D focus on mitigating radiation-induced injuries (Oral Mucositis & Acute Radiation Syndrome) and chronic rhinosinusitis. | Open | anti-inflammatory, mucositis, periodontitis, glycobiology, radiation biology, inflammation, cancer supportive care, palliative care, Chronic Rhinosunusitis | Open | 675 Arapeen Drive Ste 302 | Salt Lake City | UT | US | 84108 | GlycoMira Therapeutics Inc. | Pharmaceuticals & Biotechnology | ||
private:glycomiratherapeuticsinc.-2 | 1464055 | Nov 7th, 2017 12:00AM | GlycoMira Therapeutics, Inc. | 47 | 6.00 | Open | Biotechnology | Nov 7th, 2017 05:55PM | Nov 7th, 2017 05:55PM | GlycoMira Therapeutics is developing therapeutics for Mucosal Diseases. Current R&D focus on mitigating radiation-induced injuries (Oral Mucositis & Acute Radiation Syndrome) and chronic rhinosinusitis. | GlycoMira Therapeutics Inc. | Pharmaceuticals & Biotechnology | ||||||||||
private:glycomiratherapeuticsinc.-2 | 1464055 | Nov 1st, 2017 12:00AM | GlycoMira Therapeutics, Inc. | 47 | 6.00 | Open | Biotechnology | Nov 1st, 2017 05:36AM | Nov 1st, 2017 05:36AM | GlycoMira Therapeutics is developing therapeutics for Mucosal Diseases. Current R&D focus on mitigating radiation-induced injuries (Oral Mucositis & Acute Radiation Syndrome) and chronic rhinosinusitis. | GlycoMira Therapeutics Inc. | Pharmaceuticals & Biotechnology |